Anchor Therapeutics designs and
develops peptide modulators of G protein-coupled receptors (GPCRs), the
largest family of drug targets. Anchor’s peptides, called pepducins,
modulate GPCR activity utilizing a unique intracellular allosteric mechanism
that is well suited for a wide variety of targets, including intractable and
orphan receptors. Anchor and its pharma
collaborators are leveraging the broad applications of pepducin
technology to create new treatment options for regenerative medicine,
diabetes, inflammation and cancer.